Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Golcamide, Poseltinib, and Rituximab in Relapsed/Refractory Large B-Cell Lymphoma
KCT0011675Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poseltinib, rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Bristol Myers Squibb. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
poseltinibrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0011675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011675.